Search

Your search keyword '"Chua, Terrance S. J."' showing total 12 results
Start Over Author "Chua, Terrance S. J." Publication Year Range Last 10 years
12 results on '"Chua, Terrance S. J."'

2. Outcomes of Investigating T Wave Inversion With Echocardiography in an Unselected Young Male Preparticipation Cohort

Author

Ho, Wilbert H. H., primary, Lim, Daniel Y. Z., additional, Thiagarajan, Nishanth, additional, Wang, Hankun, additional, Loo, Wesley T. W., additional, Sng, Gerald G. R., additional, Lee, Joshua S. W., additional, Shen, Xiayan, additional, Dalakoti, Mayank, additional, Sia, Ching‐Hui, additional, Tan, Benjamin Y. Q., additional, Lim, Huai Yang, additional, Wang, Luo‐Kai, additional, Chow, Weien, additional, Chua, Terrance S. J., additional, Lim, Paul C. Y., additional, Yeo, Tee Joo, additional, and Chong, Daniel T. T., additional

Published
2023
Full Text
View/download PDF

4. Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)

Author

Vallejo-Vaz, Antonio J., Marco, Martina De, Stevens, Christophe A. T., Akram, Asif, Freiberger, Tomas, Hovingh, G. Kees, Kastelein, John J. P., Mata, Pedro, Raal, Frederick J., Santos, Raul D., Soran, Handrean, Watts, Gerald F., Abifadel, Marianne, Aguilar-Salinas, Carlos A., Al-Khnifsawi, Mutaz, Alkindi, Fahad A., Alnouri, Fahad, Alonso, Rodrigo, Al-Rasadi, Khalid, Al-Sarraf, Ahmad, Ashavaid, Tester F., Binder, Christoph J., Bogsrud, Martin P., Bourbon, Mafalda, Bruckert, Eric, Chlebus, Krzysztof, Corral, Pablo, Descamps, Olivier, Durst, Ronen, Ezhov, Marat, Fras, Zlatko, Genest, Jacques, Groselj, Urh, Harada-Shiba, Mariko, Kayikcioglu, Meral, Lalic, Katarina, Lam, Carolyn S. P., Latkovskis, Gustavs, Laufs, Ulrich, Liberopoulos, Evangelos, Lin, Jie, Maher, Vincent, Majano, Nelson, Marais, A. David, März, Winfried, Mirrakhimov, Erkin, Miserez, André R., Mitchenko, Olena, Nawawi, Hapizah M., Nordestgaard, B. rge G., Paragh, György, Petrulioniene, Zaneta, Pojskic, Belma, Postadzhiyan, Arman, Reda, Ashraf, Reiner, Željko, Sadoh, Wilson E., Sahebkar, Amirhossein, Shehab, Abdullah, Shek, Aleksander B., Stoll, Mario, Su, Ta-Chen, Subramaniam, Tavintharan, Susekov, Andrey V., Symeonides, Phivos, Tilney, Myra, Tomlinson, Brian, Truong, Thanh-Huong, Tselepis, Alexandros D., Tybjærg-Hansen, Anne, Vázquez-Cárdenas, Alejandra, Viigimaa, Margus, Vohnout, Branislav, Widén, Elisabeth, Yamashita, Shizuya, Banach, Maciej, Gaita, Dan, Jiang, Lixin, Nilsson, Lennart, Santos, Lourdes E., Schunkert, Heribert, Tokgözoğlu, Lale, Car, Josip, Catapano, Alberico L., Ray, Kausik K., Schreier, Laura, Pang, Jing, Dieplinger, Hans, Hanauer-Mader, Gabriele, Desutter, Johan, Langlois, Michel, Mertens, Ann, Rietzschel, Ernst, Wallemacq, Caroline, Isakovic, Dzenana, Dzankovic, Amra M., Obralija, Jasna, Pojskic, Lamija, Sisic, Ibrahim, Stimjanin, Ena, Torlak, Vildana A., Jannes, Cinthia E., Krieger, Jose E., Pereira, Alexandre C., Ruel, Isabelle, Asenjo, Sylvia, Cuevas, Ada, Pećin, Ivan, Miltiadous, George, Panayiotou, Andrie G., Vrablik, Michal, Benn, Marianne, Heinsar, Silver, Béliard, S., Gouni-Berthold, Ioanna, Hengstenberg, Wibke, Julius, Ulrich, Kassner, Ursula, Klose, Gerald, König, Christel, König, Wolfgang, Otte, Britta, Parhofer, Klaus, Schatz, Ulrike, Schmidt, Nina, Steinhagen-Thiessen, Elisabeth, Vogt, Anja, Antza, Christina, Athyros, Vasilios, Bilianou, Eleni, Boufidou, Amalia, Chrousos, George, Elisaf, Moses, Garoufi, Anastasia, Katsiki, Niki, Kolovou, Genovefa, Kotsis, Vasilios, Rallidis, Loukianos, Rizos, Christos, Skalidis, Emmanouel, Skoumas, Ioannis, Tziomalos, Kostantinos, Shawney, J. P. S., Abbaszadegan, Mohammad R., Aminzadeh, Majid, Hosseini, Sousan, Mobini, Moein, Vakili, Rahim, Zaeri, Hossein, Agar, Ruth, Boran, Gerard, Colwell, Nial, Crowley, Vivion, Durkin, Maeve, Griffin, Damian, Kelly, Michael, Rakovac-Tisdall, Ana, Bitzur, Rafael, Cohen, Hofit, Eliav, Osnat, Ellis, Avishay, Gavish, Dov, Harats, Dror, Henkin, Yaacov, Knobler, Hila, Leavit, Leah, Leitersdorf, Eran, Rubinstein, Ardon, Schurr, Daniel, Shpitzen, Shoshi, Szalat, Auryan, Arca, Marcello, Averna, Maurizio, Bertolini, Stefano, Calandra, Sebastiano, Tarugi, Patrizia, Erglis, Andrejs, Gilis, Dainus, Nesterovics, Georgijs, Saripo, Vita, Upena-Roze, Arta, Elbitar, Sandy, Jambart, S. lim, Khoury, Petra El, Gargalskaite, Urte, Kutkiene, Sandra, Al-Khateeb, Alyaa, An, Chua Y., Ismail, Zaliha, Kasim, Sazzli, Ibrahim, Khairul S., Radzi, Ahmad B. M., Kasim, Noor A., Nor, Noor S. M., Ramli, Anis S., Razak, Suraya A., Muid, Suhaila, Rosman, Azhari, Sanusi, Abd R., Razman, Aimi Z., Nazli, Sukma A., Kek, Teh L., Azzopardi, Conrad, Aguilar Salinas, Carlos A., Vázquez-Cárdenas, N. Alejandra, Galán, Gabriela, Magaña-Torres, M. T., Martagon, Alexandro, Mehta, Roopa, Wittekoek, M. E., Isara, Alphonsus R., Obaseki, Darlington E., Ohenhen, Oluwatoyin A., Holven, Kirsten B., Gruchała, Marcin, Baranowska, Marlena, Borowiec-Wolny, Justyna, Gilis-Malinowska, Natasza, Michalska-Grzonkowska, Aleksandra, Pajkowski, Marcin, Parczewska, Aleksandra, Romanowska-Kocejko, Marzena, Stróżyk, Aneta, Żarczyńska-Buchowiecka, Marta, Kleinschmidt, Mariola, Alves, Ana C., Medeiros, Ana M., Ershova, Alexandra, Korneva, Victoria, Kuznetsova, Tatiana, Malyshev, Pavel, Meshkov, Alexey, Rozhkova, Tatiana, Rajkovic, Natasa, Popovic, Ljiljana, Lukac, Sandra S., Stosic, Ljubica, Rasulic, Iva, Lalic, Nebojsa M., Chua, Terrance S. J., Ting, Sharon P. L., Raslova, Katarina, Battelino, Tadej, Cevc, Matija, Jug, Borut, Kovac, Jernej, Podkrajsek, Katarina T., Sustar, Ursa, Trontelj, Katja J., Marais, David, Isla, Leopoldo Perez de, Martin, François J., Charng, Ming-Ji, Chen, Pei-Lung, Kayikçioglu, Meral, Dell’oca, Nicolás, Fernández, Graciela, Ressia, Andrés, Reyes, Ximena, Zelarayan, Mario, Alieva, Rano B., Hoshimov, Shavkat U., Kurbanov, Ravshanbek D., Nizamov, Ulugbek I., Lima-Martínez, Marcos M., Nguyen, Mai-Ngoc Thi, Do, Doan-Loi, Kim, Ngoc-Thanh, le, Hong-An, le, Thanh-Tung, Centre of Excellence in Complex Disease Genetics, Elisabeth Ingrid Maria Widen / Principal Investigator, Institute for Molecular Medicine Finland, University of Helsinki, Genomic Discoveries and Clinical Translation, Kardiyoloji, Lee Kong Chian School of Medicine (LKCMedicine), Pfizer Incorporated, European Atherosclerosis Society, ACS - Atherosclerosis & ischemic syndromes, Vascular Medicine, ACS - Pulmonary hypertension & thrombosis, and Ege Üniversitesi

Subjects
International Cooperation, MÉTODOS EPIDEMIOLÓGICOS, 030204 cardiovascular system & hematology, Nationwide survey, Global Health, Health Services Accessibility, Doenças Cardio e Cérebro-vasculares, MOLECULAR-GENETICS, 0302 clinical medicine, Risk Factors, Prevalence, CARDIOVASCULAR RISK-FACTORS, 030212 general & internal medicine, Cooperative Behavior, DEFECTIVE APOLIPOPROTEIN B-100, GENERAL-POPULATION, education.field_of_study, medicine.diagnostic_test, Anticholesteremic Agents, Familial hypercholesterolaemia, FHSC, Primary dyslipidaemia, Biomarkers, Cholesterol, LDL, Genetic Predisposition to Disease, Health Care Surveys, Healthcare Disparities, Humans, Hyperlipoproteinemia Type II, Phenotype, Predictive Value of Tests, Treatment Outcome, Blood Component Removal, EAS Familial Hypercholesterolaemia Studies Collaboration, 3. Good health, PREVALENCE, Cholesterol, CORONARY-ARTERY-DISEASE, NATIONWIDE SURVEY, Cardiology and Cardiovascular Medicine, medicine.medical_specialty, Cardiovascular risk factors, Population, LDL-RECEPTOR, 1102 Cardiovascular Medicine And Haematology, LDL, 03 medical and health sciences, medicine, Medicine [Science], fhsc, familial hypercholesterolaemia, primary dyslipidaemia, education, Genetic testing, Government, Public health, EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC) Investigators, SAFEHEART REGISTRY, 1103 Clinical Sciences, Cardiovascular System & Hematology, Family medicine, 3121 General medicine, internal medicine and other clinical medicine, Cardiovascular System & Cardiology, Business, FOLLOW-UP
Abstract

PubMed: 30270054, 2-s2.0-85053666909, Background and aims: Management of familial hypercholesterolaemia (FH) may vary across different settings due to factors related to population characteristics, practice, resources and/or policies. We conducted a survey among the worldwide network of EAS FHSC Lead Investigators to provide an overview of FH status in different countries. Methods: Lead Investigators from countries formally involved in the EAS FHSC by mid-May 2018 were invited to provide a brief report on FH status in their countries, including available information, programmes, initiatives, and management. Results: 63 countries provided reports. Data on FH prevalence are lacking in most countries. Where available, data tend to align with recent estimates, suggesting a higher frequency than that traditionally considered. Low rates of FH detection are reported across all regions. National registries and education programmes to improve FH awareness/knowledge are a recognised priority, but funding is often lacking. In most countries, diagnosis primarily relies on the Dutch Lipid Clinics Network criteria. Although available in many countries, genetic testing is not widely implemented (frequent cost issues). There are only a few national official government programmes for FH. Under-treatment is an issue. FH therapy is not universally reimbursed. PCSK9-inhibitors are available in ?2/3 countries. Lipoprotein-apheresis is offered in ?60% countries, although access is limited. Conclusions: FH is a recognised public health concern. Management varies widely across countries, with overall suboptimal identification and under-treatment. Efforts and initiatives to improve FH knowledge and management are underway, including development of national registries, but support, particularly from health authorities, and better funding are greatly needed. © 2018 Elsevier B.V., Universidade de São Paulo, USP European Atherosclerosis Society, EAS Amgen Merck Sharp and Dohme, MSD, The ELSA Study suggests heterozygous FH (HeFH) may affect 1:263 Brazilians (?766,000 individuals). Currently, the only active genetic cascade screening program in Brazil is Hipercol Brasil in Sao Paulo (genetic testing for adults with low-density lipoprotein cholesterol (LDL-C) ?230?mg/dL, to maximise cost-effectiveness), with 1719 heterozygotes, 25 homozygotes, 13 compound-heterozygotes and one double-heterozygote identified by March 2018. To date, 4340 individuals from 440 families were screened. Genetic testing is funded by a government tax reduction programme (PROADI-SUS), and cascade screening by partnering between Samaritano Hospital and Heart Institute (InCor) University of Sao Paulo. Most FH patients are under non-specialist care and currently under-treated., Prevalence is unknown but assumed at 1:250. There is no state programme and few patients were diagnosed before the Latvian FH Registry was established in 2015. To date, the Registry has identified 181 cases (2.3% of 7876 estimated HeFH cases; no HoFH). Cascade screening is performed in first-degree relatives of index cases with probable/definite FH. Genetic testing is not reimbursed but has been funded by research grants for a few patients/relatives. About 5% of patients had LDL-C at target before inclusion in the Registry [ 61 ]. Statins are reimbursed 50% in primary prevention; statins and ezetimibe, 75–100% in secondary prevention; PCSK9i are available, but not reimbursed., Estimated prevalence is 1:250 (based on a meta-analysis of 6 observational studies) or 136,300 adults (only 2% diagnosed) [ 69 , 70 ]. Based on LIPIDOGRAM studies (2004–2015, ?50,000 participants), prevalence might be?1:200 [ 71 , 72 ]. Five HoFH cases are described [ 73 , 74 ]. Patients with DLCN ?3 are referred for genetic testing, funded by the National Health Program. The National Centre for FH at University Clinical Hospital, Medical University of Gdansk, was established in 2017, financed by the Ministry of Health. From August 2017, 345 patients underwent genetic testing (153 positive, including 46 relatives; 1 HoFH). Since 1999, 1884 patients (562 families) have undergone genetic testing and cascade diagnosis (data from the National Polish FH Registry, Medical University of Gdansk, established in 2000). PCSK9i are not reimbursed (under discussion with the Ministry of Health)., The EAS FHSC project has received support from a Pfizer Independent Grant for Learning & Change 2014 (No: 16157823 ) and from investigator-initiated unrestricted research grants to the European Atherosclerosis Society from Amgen , MSD , and Sanofi-Aventis .

Published
2018

5. Machine learning versus classical electrocardiographic criteria for echocardiographic left ventricular hypertrophy in a pre-participation cohort.

Author

Lim, Daniel Y. Z., Sng, Gerald, Ho, Wilbert H. H., Wang Hankun, Ching-Hui Sia, Lee, Joshua S. W., Xiayan Shen, Tan, Benjamin Y. Q., Lee, Edward C. Y., Dalakoti, Mayank, Wang Kang Jie, Kwan, Clarence K. W., Weien Chow, Ru San Tan, Lam, Carolyn S. P., Chua, Terrance S. J., Tee Joo Yeo, and Chong, Daniel T. T.

Published
2021
Full Text
View/download PDF

6. A Population‐wide study of electrocardiographic (ECG) norms and the effect of demographic and anthropometric factors on selected ECG characteristics in young, Southeast Asian males—results from the Singapore Armed Forces ECG (SAFE) study

Author

Sia, Ching‐Hui, primary, Dalakoti, Mayank, additional, Tan, Benjamin Y. Q., additional, Lee, Edward C. Y., additional, Shen, Xiayan, additional, Wang, Kangjie, additional, Lee, Joshua S., additional, Arulanandam, Shalini, additional, Chow, Weien, additional, Yeo, Tee Joo, additional, Yeo, Khung Keong, additional, Chua, Terrance S. J., additional, Tan, Ru San, additional, Lam, Carolyn S. P., additional, and Chong, Daniel T. T., additional

Published
2019
Full Text
View/download PDF

8. Intergenerational transfer of blood pressure knowledge and screening: a school-based hypertension awareness program in Singapore.

Author

Lwin, May O., Malik, Shelly, Chua, Terrance S. J., Chee, Tek Siong, and Tan, Yong Seng

Abstract

Objective: This study aims to examine the efficacy of a hypertension awareness education program in Singapore in reaching out to a wider population of diverse racial and intergenerational cohorts by dispatching grade five children as information intermediaries to their immediate and extended family members.Method: After receiving structured instruction and training on blood pressure screening, students were requested to share knowledge gained in school with their family members at home and practice blood pressure measurement on family volunteers. We assessed pre- and post-program blood pressure knowledge change, attitude toward screening, and the diffusion of blood pressure information. One adult family member was also asked to complete a short survey at the program end.Results: A comparison of the students' (final n = 3926) pre- and post-program survey data showed that knowledge and attitudes towards knowledge sharing improved after participating in the program. The post-program survey also revealed that students generally felt confident and displayed positive attitudes in performing blood pressure screening on family members. On average, each student practiced blood pressure measurement on 3.04 people. Female family members were more likely to be targeted for knowledge sharing and screening than male family members. The family members' survey revealed positive attitudes towards screening, but family members were not confident about getting their measurements done regularly.Conclusion: The program met its objectives in raising the awareness of grade five children and provision of knowledge. It also met the larger objective of raising hypertension awareness in a wider population, especially those who otherwise might not directly receive health education and blood pressure screening. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

10. Prevalence of Brugada Syndrome in a Large Population of Young Singaporean Men.

Author

Shen X, Tan BYQ, Sia CH, Lee JSW, Dalakoti M, Wang K, Lim DYZ, Sng GGR, Lee ECY, Chow W, Kwan CKW, Wang LK, Tan BY, Lim PCY, Chua KCM, Ho KL, Lim ETS, Ching CK, Teo WS, Chua TSJ, Tan RS, Yeo TJ, and Chong DTT

Subjects
Adolescent, Brugada Syndrome epidemiology, Brugada Syndrome ethnology, Electrocardiography, Flecainide adverse effects, Flecainide therapeutic use, Humans, Male, Prevalence, ST Elevation Myocardial Infarction physiopathology, Singapore epidemiology, Sodium Channel Blockers adverse effects, Sodium Channel Blockers therapeutic use, Young Adult, Brugada Syndrome diagnosis
Published
2020
Full Text
View/download PDF

11. Sex Differences in 1-Year Rehospitalization for Heart Failure and Myocardial Infarction After Primary Percutaneous Coronary Intervention.

Author

Zheng H, Foo LL, Tan HC, Richards AM, Chan SP, Lee CH, Low AFH, Hausenloy DJ, Tan JWC, Sahlen AO, Ho HH, Chai SC, Tong KL, Tan DSY, Yeo KK, Chua TSJ, Lam CSP, and Chan MY

Subjects
Aged, Drug-Eluting Stents, Female, Heart Failure therapy, Humans, Male, Middle Aged, Platelet Aggregation Inhibitors therapeutic use, Proportional Hazards Models, Retrospective Studies, Sex Factors, Time Factors, Time-to-Treatment, Treatment Outcome, Heart Failure epidemiology, Myocardial Infarction epidemiology, Myocardial Infarction therapy, Patient Readmission statistics & numerical data, Percutaneous Coronary Intervention
Abstract

It is unclear whether universal access to primary percutaneous coronary intervention (pPCI) may reduce sex differences in 1-year rehospitalization for heart failure (HF) and myocardial infarction (MI) after ST-elevation myocardial infarction (STEMI). We studied 7,597 consecutive STEMI patients (13.8% women, n = 1,045) who underwent pPCI from January 2007 to December 2013. Cox regression models adjusted for competing risk from death were used to assess sex differences in rehospitalization for HF and MI within 1 year from discharge. Compared with men, women were older (median age 67.6 vs 56.0 years, p < 0.001) with higher prevalence of co-morbidities and multivessel disease. Women had longer median door-to-balloon time (76 vs 66 minutes, p < 0.001) and were less likely to receive drug-eluting stents (19.5% vs 24.1%, p = 0.001). Of the medications prescribed at discharge, fewer women received aspirin (95.8% vs 97.6%, p = 0.002) and P2Y 12 antagonists (97.6% vs 98.5%, p = 0.039), but there were no significant sex differences in other discharge medications. After adjusting for differences in baseline characteristics and treatment, sex differences in risk of rehospitalization for HF attenuated (hazard ratio [HR] 1.05, 95% confidence interval [CI] 0.79 to 1.40), but persisted for MI (HR 1.68, 95% CI 1.22 to 2.33), with greater disparity in patients aged ≥60 years (HR 1.83, 95% CI 1.18 to 2.85) than those aged <60 years (HR 1.45, 95% CI 0.84 to 2.50). In conclusion, in a setting of universal access to pPCI, the adjusted risk of 1-year rehospitalization for HF was similar in both sexes, but women had significantly higher adjusted risk of 1-year rehospitalization for MI, especially older women., (Copyright © 2019. Published by Elsevier Inc.)

Published
2019
Full Text
View/download PDF

12. Long-Term Prognostic Value of Appropriate Myocardial Perfusion Imaging.

Author

Koh AS, Lye WK, Chia SY, Salunat-Flores J, Sim LL, Keng FYJ, Tan RS, and Chua TSJ

Subjects
Cause of Death trends, Electrocardiography, Female, Follow-Up Studies, Humans, Image Processing, Computer-Assisted, Male, Middle Aged, Myocardial Ischemia mortality, Predictive Value of Tests, Prognosis, Prospective Studies, Reproducibility of Results, Retrospective Studies, Singapore epidemiology, Survival Rate trends, Time Factors, Tomography, Emission-Computed, Single-Photon methods, Myocardial Ischemia diagnosis, Myocardial Perfusion Imaging methods
Abstract

Appropriate use criteria (AUC) for single-photon emission computed tomography myocardial perfusion images (SPECT-MPIs) were developed to address the growth of cardiac imaging studies. Long-term prognostic value of AUC in SPECT-MPI has not been tested in existing cohorts. We sought to determine the long-term prognostic value of MPI classified as appropriate. AUC was evaluated in a prospectively designed cohort of patients who underwent clinically indicated MPI. MPI studies were classified based on 2009 AUC for SPECT-MPI. Data regarding downstream coronary angiography (cath), revascularization and all-cause mortality, cardiac death, and nonfatal myocardial infarction (MI) were collected from national registries. Among n = 1,129 MPI scans that received an appropriate grading, 148 all-cause deaths, 109 MIs, 58 cardiac deaths, 152 caths, 113 revascularization procedures occurred over a mean follow-up period of 5.4 ± 1.2 years (0.9% cardiac death rate per year, 1.8% MI rate per year). Most of the scans were low-risk normal MPI scans (summed stress score ≤3; 74.1%). An abnormal scan was associated with higher rates of MI (19.5% vs 6.2%, hazard ratio 1.72, p = 0.017) and cardiac death (13.4% vs 2.3%, hazard ratio 2.12, p = 0.016). In conclusion, MPI scans classified as appropriate have long-term prognostic value, despite a high proportion of low-risk scans. This provides support for clinicians to consider the use of appropriate grading in addition to MPI scan results in patient management., (Copyright © 2017 Elsevier Inc. All rights reserved.)

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results